# OnCo record paper-javle-mypathway-her2-biliary-lancet-oncol-2021 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-javle-mypathway-her2-biliary-lancet-oncol-2021/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-javle-mypathway-her2-biliary-lancet-oncol-2021" ;
  schema:name "Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study"@en ;
  schema:description "Two HER2 antibodies together shrank tumours in about a quarter of 39 patients with HER2-positive bile duct or gallbladder cancer that had already been treated, with manageable side effects, prompting the later randomised HER2 trials."@en ;
  schema:url <https://onco.cc/key-papers/paper-javle-mypathway-her2-biliary-lancet-oncol-2021/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/s1470-2045(21)00336-3>, <https://pubmed.ncbi.nlm.nih.gov/34339623/>, <https://clinicaltrials.gov/study/NCT02091141> ;
  schema:sameAs <https://doi.org/10.1016/s1470-2045(21)00336-3> ;
  schema:datePublished "2021"^^xsd:gYear ;
  schema:author "Javle M, Borad MJ, Azad NS, et al." ;
  onco:cancers <https://onco.cc/cancers/gallbladder/>, <https://onco.cc/cancers/biliary-tract-cancer/>, <https://onco.cc/cancers/cholangiocarcinoma/> ;
  onco:targets <https://onco.cc/targets/her2/> ;
  onco:drugs <https://onco.cc/drugs/pertuzumab/>, <https://onco.cc/drugs/trastuzumab/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> ;
  onco:trials <https://onco.cc/trials/mypathway/> ;
  onco:people <https://onco.cc/people/ghassan-abou-alfa/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .